Observational studyCancer medicine2020
Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection.
Observational study in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Prognostic and clinicopathological importance of microRNA-140 expression in cancer patients: a meta-analysis.World journal of surgical oncology · 2021Pooled it
- Review
- An immune-related miRNA signature predicts the prognosis in nasopharyngeal carcinoma.Translational cancer research · 2025Article
- Precision Medicine for Nasopharyngeal Cancer-A Review of Current Prognostic Strategies.Cancers · 2024Review
- Tumor-derived small extracellular vesicles in cancer invasion and metastasis: molecular mechanisms, and clinical significance.Molecular cancer · 2024Review
- Diagnostic model for hepatocellular carcinoma using small extracellular vesicle-propagated miRNA signatures.Frontiers in molecular biosciences · 2024Article
- Application of small extracellular vesicles in the diagnosis and prognosis of nasopharyngeal carcinoma.Frontiers in cell and developmental biology · 2023Review
- Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.International journal of molecular sciences · 2022Review
- Circulating microRNAs as the Potential Diagnostic and Prognostic Biomarkers for Nasopharyngeal Carcinoma.Genes · 2022Review
- Multiple microRNA signature panel as promising potential for diagnosis and prognosis of head and neck cancer.Molecular biology reports · 2022Review
- Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples.PloS one · 2022Article
- General Features and Novel Gene Signatures That Identify Epstein-Barr Virus-Associated Epithelial Cancers.Cancers · 2021Article
- Aberrant long non-coding RNA cancer susceptibility 15 (CASC15) plays a diagnostic biomarker and regulates inflammatory reaction in neonatal sepsis.Bioengineered · 2021Article
- Review
- Current Status and Future Perspectives about Molecular Biomarkers of Nasopharyngeal Carcinoma.Cancers · 2021Review
- The progress, prospects, and challenges of the use of non-coding RNA for diabetic wounds.Molecular therapy. Nucleic acids · 2021Review
- miRNAs derived from circulating small extracellular vesicles as diagnostic biomarkers for nasopharyngeal carcinoma.Cancer science · 2021Article
- Circulating miRNAs Act as Diagnostic Biomarkers for Bladder Cancer in Urine.International journal of molecular sciences · 2021Article
- Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high‑throughput omics (Review).International journal of oncology · 2021Review
- An Oxidative Stress-Related Gene Pair (Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating microRNAs (miRNAs) have become reliable sources of non-invasive biomarkers for cancer diagnosis. Identification of promising miRNA biomarkers in plasma might benefit a lot to the detection of nasopharyngeal carcinoma (NPC).
methodsThe Exiqon miRNA qPCR panel was used in the screening stage to identify candidate miRNAs, which were further verified by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in the following three stages among plasma samples from 200 NPC patients and 189 healthy donors (as normal controls [NCs]). The identified miRNAs were further explored in tissue specimens (48 NPC vs 32 NCs) and plasma exosomes (32 NPC vs 32 NCs). Survival analyses were ultimately conducted by Cox regression models and Kaplan-Meier curves using log-rank tests.
resultsWe identified a 7-miRNA signature including let-7b-5p, miR-140-3p, miR-144-3p, miR-17-5p, miR-20a-5p, miR-20b-5p, and miR-205-5p in plasma for NPC diagnosis after four-stage validation. The areas under the receiver operating characteristic curve (AUCs) for the signature were 0.879, 0.884, 0.921, and 0.807 for the training, testing, external validation stage, and the combined three stages, respectively. In NPC tissues, miR-144-3p, miR-17-5p, miR-20a-5p, and miR-205-5p were consistently up-regulated while let-7b-5p and miR-140-3p were significantly down-regulated compared to NCs. However, none of the seven identified miRNAs were dysregulated in plasma-derived exosomes in NPC patients. As to survival analysis, none of the seven miRNAs seemed to be associated with NPC prognosis.
conclusionWe identified a 7-miRNA signature in plasma as promising non-invasive biomarkers for NPC detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.